Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_assertion type Assertion NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_head.
- NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_assertion description "[Analysis of phenotypes by genotype revealed only small differences between the Pro/Pro and Ala/- groups, respectively, in baseline S(i) (2.76 +/- 0.19 vs. 2.33 +/- 0.33 x 10(-4) min(-1) per microU/ml; P = 0.27), the change in S(i) after 3 months of troglitazone treatment (1.19 +/- 0.17 vs. 0.93 +/- 0.30; P = 0.46), and the cumulative incidence of diabetes during a median follow-up of 30 months (13 vs. 17%; P = 0.66).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_provenance.
- NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_assertion evidence source_evidence_literature NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_provenance.
- NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_assertion SIO_000772 15161789 NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_provenance.
- NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_assertion wasDerivedFrom befree-2016 NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_provenance.
- NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_assertion wasGeneratedBy ECO_0000203 NP445611.RAJZj0i2ds3tQkVDb6rmSfER-n7VbItZMkhmSMFfCPMvQ130_provenance.